Phathom Pharmaceuticals Short Long Term Debt Total Over Time
| PHAT Stock | USD 5.06 0.84 14.24% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Phathom Pharmaceuticals Performance and Phathom Pharmaceuticals Correlation. Phathom |
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Phathom Pharmaceuticals. If investors know Phathom will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Phathom Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Phathom Pharmaceuticals is measured differently than its book value, which is the value of Phathom that is recorded on the company's balance sheet. Investors also form their own opinion of Phathom Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Phathom Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Phathom Pharmaceuticals' market value can be influenced by many factors that don't directly affect Phathom Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Phathom Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Phathom Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Phathom Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Short Long Term Debt Total Analysis
Compare Phathom Pharmaceuticals and related stocks such as Day One Biopharmaceu, Blueprint Medicines Corp, and Lyra Therapeutics Short Long Term Debt Total Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DAWN | 402 K | 402 K | 402 K | 402 K | 402 K | 402 K | 402 K | 402 K | 402 K | 402 K | 402 K | 220 K | 813 K | 408 K | 2.6 M | 2.7 M |
| BPMC | 2.9 M | 2.9 M | 2.9 M | 2.9 M | 9 M | 7.9 M | 4.6 M | 16.3 M | 14.6 M | 95.9 M | 89.6 M | 111.4 M | 562.7 M | 774.1 M | 126.1 M | 166.4 M |
| LYRA | 3.3 M | 3.3 M | 3.3 M | 3.3 M | 3.3 M | 3.3 M | 3.3 M | 3.3 M | 3.3 M | 3.3 M | 2.4 M | 1.5 M | 2.2 M | 26.9 M | 30.9 M | 32.5 M |
| CGEM | 5.2 M | 5.2 M | 5.2 M | 5.2 M | 5.2 M | 5.2 M | 5.2 M | 5.2 M | 5.2 M | 5.2 M | 5.2 M | 5.2 M | 5.2 M | 3.6 M | 2.2 M | 2.9 M |
| ABOS | 201 K | 201 K | 201 K | 201 K | 201 K | 201 K | 201 K | 201 K | 201 K | 201 K | 201 K | 201 K | 105 K | 28.5 M | 32.8 M | 34.4 M |
| XFOR | 7.2 M | 7.2 M | 7.2 M | 7.2 M | 7.2 M | 7.2 M | 15.3 M | 12.2 M | 9.6 M | 22.9 M | 38.4 M | 39.8 M | 38.4 M | 58.3 M | 67 M | 70.4 M |
| INZY | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 3.4 M | 6.8 M | 46.6 M | 53.6 M | 56.3 M |
| KNSA | 2.7 M | 2.7 M | 2.7 M | 2.7 M | 2.7 M | 2.7 M | 2.7 M | 2.7 M | 2.7 M | 2.7 M | 7 M | 6 M | 5.9 M | 12.3 M | 9.9 M | 8 M |
| GPCR | 280 | 280 | 280 | 280 | 280 | 280 | 280 | 280 | 280 | 280 | 280 | 621 | 260 K | 5.5 M | 3.9 M | 2.1 M |
| IMMX | 4.1 M | 4.1 M | 4.1 M | 4.1 M | 4.1 M | 4.1 M | 4.1 M | 4.1 M | 4.1 M | 4.1 M | 4.1 M | 50 K | 50 K | 50 K | 45 K | 42.8 K |
| CNSP | 121.8 K | 121.8 K | 121.8 K | 121.8 K | 121.8 K | 121.8 K | 121.8 K | 121.8 K | 316.9 K | 439.3 K | 439.3 K | 387.8 K | 410 K | 300.8 K | 345.9 K | 362.4 K |
| HEPA | 10.4 K | 10.4 K | 10.4 K | 10.4 K | 10.4 K | 10.4 K | 10.4 K | 1.4 M | 1.4 M | 807.4 K | 752.2 K | 317 K | 53.6 K | 209 K | 188.1 K | 338.6 K |
| TERN | 12.9 M | 12.9 M | 12.9 M | 12.9 M | 12.9 M | 12.9 M | 12.9 M | 12.9 M | 12.9 M | 12.9 M | 12.9 M | 1.2 M | 1.2 M | 603 K | 542.7 K | 515.6 K |
Phathom Pharmaceuticals and related stocks such as Day One Biopharmaceu, Blueprint Medicines Corp, and Lyra Therapeutics Short Long Term Debt Total description
My Equities
My Current Equities and Potential Positions
| Phathom Pharmaceuticals | PHAT |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | New Jersey; U.S.A |
| Exchange | NASDAQ Exchange |
USD 4.85
Additional Tools for Phathom Stock Analysis
When running Phathom Pharmaceuticals' price analysis, check to measure Phathom Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Phathom Pharmaceuticals is operating at the current time. Most of Phathom Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Phathom Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Phathom Pharmaceuticals' price. Additionally, you may evaluate how the addition of Phathom Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.